deltatrials
Terminated PHASE4 INTERVENTIONAL 1-arm NCT03656692

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU)

Sponsor: Mallinckrodt

Conditions Panuveitis Uveitis, Intermediate Uveitis, Posterior
Interventions Acthar Gel
Updated 15 times since 2018 Last updated: Jul 12, 2021 Started: Oct 5, 2018 Primary completion: Jul 14, 2020 Completion: Jul 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Logistical challenges; no safety concerns

Other terminated trials from Mallinckrodt

See all terminations from Mallinckrodt

A PHASE4 clinical study on Panuveitis and Uveitis, Intermediate, this trial is terminated or withdrawn. The trial is conducted by Mallinckrodt and has accumulated 15 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Mar 2020 · 9 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Sep 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Jan 2021 — Sep 2021 [monthly]

    Terminated PHASE4

  5. Aug 2020 — Jan 2021 [monthly]

    Terminated PHASE4

    Status: Suspended → Terminated

▶ Show 10 earlier versions

  1. Jun 2020 — Aug 2020 [monthly]

    Suspended PHASE4

  2. May 2020 — Jun 2020 [monthly]

    Suspended PHASE4

    Status: Recruiting → Suspended

  3. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE4

  4. Jun 2019 — Mar 2020 [monthly]

    Recruiting PHASE4

  5. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE4

  6. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE4

  7. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE4

  8. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE4

  9. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  10. Oct 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mallinckrodt
Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations